Filtros de búsqueda

Lista de obras de Mikko Niemi

A mechanistic, model-based approach to safety assessment in clinical development

artículo científico publicado en 2012

ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.

artículo científico publicado en 2008

ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

artículo científico publicado en 2009

Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17.

artículo científico publicado en 2005

Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children

artículo científico publicado en 2017

Analgesic Plasma Concentrations of Oxycodone After Surgery for Breast Cancer-Which Factors Matter?

artículo científico publicado en 2017

Applications of genomic medicine in the treatment of diseases

artículo científico publicado en 2017

Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics

CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe

artículo científico publicado en 2009

CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single-dose primaquine

artículo científico publicado en 2014

CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study

artículo científico publicado en 2005

Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans

Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans.

artículo científico publicado en 2015

Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice

artículo científico publicado en 2004

Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism

artículo científico publicado en 2007

Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions .

artículo científico publicado en 2017

Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin

article

Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel

scientific article published on 09 August 2018

Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone.

artículo científico publicado en 2016

Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans

artículo científico publicado en 2019

Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans.

artículo científico publicado en 2017

Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide

artículo científico publicado en 2005

Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics

artículo científico publicado en 2017

Cyclosporine A increases plasma concentrations and effects of repaglinide.

artículo científico publicado en 2006

Cyclosporine markedly raises the plasma concentrations of repaglinide

artículo científico publicado en 2005

Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

artículo científico publicado en 2007

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

artículo científico publicado en 2008

Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin

artículo científico publicado en 2009

Do Diuretics have Antinociceptive Actions: Studies of Spironolactone, Eplerenone, Furosemide and Chlorothiazide, Individually and with Oxycodone and Morphine

artículo científico publicado en 2016

Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses

artículo científico publicado en 2011

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

artículo científico publicado en 2006

Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications

artículo científico publicado en 2012

Drug-Related Inadvertent Deaths in a University Hospital--A Declining Trend

artículo científico publicado en 2015

Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren

artículo científico publicado en 2010

Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin

article by Mikko Niemi et al published August 2006 in Pharmacogenetics and Genomics

Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.

artículo científico publicado en 2009

Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril

artículo científico publicado en 2015

Effect of fluconazole on plasma fluvastatin and pravastatin concentrations

artículo científico publicado en 2000

Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide

artículo científico publicado en 2003

Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride

artículo científico publicado en 2001

Effect of grapefruit juice on the bioactivation of prasugrel

artículo científico publicado en 2015

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride

artículo científico publicado en 2000

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects

artículo científico publicado en 2003

Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects

artículo científico publicado en 2017

Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide

artículo científico publicado en 2007

Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride

artículo científico publicado en 2001

Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism

artículo científico publicado en 2008

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide

artículo científico publicado en 2003

Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide

artículo científico publicado en 2001

Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

artículo científico publicado en 2008

Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone

artículo científico publicado en 2004

Enantiospecific Pharmacogenomics of Fluvastatin

artículo científico publicado en 2019

Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1)

artículo científico publicado en 2005

Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations

Frequencies of Single-Nucleotide Polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 Genes in a Finnish Population

article

Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population

article

Functional interaction of intestinal CYP3A4 and P-glycoprotein

artículo científico publicado en 2004

Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses

scientific article published on 01 May 2012

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

artículo científico publicado en 2003

Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.

artículo científico publicado en 2013

Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast

artículo científico publicado en 2010

Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings

artículo científico publicado en 2011

Genome‐Wide Association Study of Atorvastatin Pharmacokinetics: Associations With <i>SLCO1B1</i>, <i>UGT1A3</i>, and <i>LPP</i>

artículo científico publicado en 2024

Global analysis of genetic variation in SLCO1B1.

artículo científico publicado en 2008

Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions

artículo científico publicado en 2014

Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes

artículo científico publicado en 2002

Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren

artículo científico publicado en 2010

Grapefruit juice inhibits the metabolic activation of clopidogrel

artículo científico publicado en 2013

Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects

artículo científico publicado en 2013

High Frequency of CYP2D6 Ultrarapid Metabolizer Genotype in the Finnish Population.

artículo científico publicado en 2016

High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma

artículo científico publicado en 2010

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

artículo científico publicado en 2004

Impact of OATP transporters on pharmacokinetics

artículo científico publicado en 2009

Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin

artículo científico publicado en 2006

Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans

artículo científico publicado en 2006

Interactions of (2S,6S;2R,6R)-Hydroxynorketamine, a Secondary Metabolite of (R,S)-Ketamine, with Morphine

artículo científico publicado en 2017

International Transporter Consortium commentary on clinically important transporter polymorphisms.

artículo científico publicado en 2013

Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction

scientific article published on 29 November 2019

Itraconazole, a P-Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin-Inhibiting Effect of Aliskiren

scholarly article by Tuija Tapaninen et al published March 2011 in The Journal of Clinical Pharmacology

Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide

article published in 2006

Ketamine and norketamine attenuate oxycodone tolerance markedly less than that of morphine: from behaviour to drug availability

scientific article published on 02 December 2017

Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat.

artículo científico publicado en 2015

Lipid-lowering response to statins is affected by CYP3A5 polymorphism

artículo científico publicado en 2004

Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism

artículo científico publicado en 2010

Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans

scientific article published on 02 March 2011

Membrane transporters in drug development

artículo científico publicado en 2010

Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone

Muscle symptoms associated with statins: a series of twenty patients

artículo científico publicado en 2006

No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin

artículo científico publicado en 2009

No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone

artículo científico publicado en 2007

No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid

Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics

artículo científico publicado en 2017

Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren

artículo científico publicado en 2011

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake

artículo científico publicado en 2011

PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo

artículo científico publicado en 2012

Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops

article published in 2014

PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.

artículo científico

Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.

artículo científico publicado en 2014

Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms

artículo científico publicado en 2008

Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin

artículo científico publicado en 2008

Pharmacokinetic interactions with rifampicin : clinical relevance

artículo científico publicado en 2003

Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes

artículo científico publicado en 2006

Pharmacokinetics of intravenous paracetamol in elderly patients

artículo científico publicado en 2011

Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole

artículo científico publicado en 2002

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

artículo científico publicado en 2005

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

artículo científico publicado en 2003

Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate

artículo científico publicado en 2008

Posaconazole‐ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatment

artículo científico publicado en 2023

Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics

artículo científico publicado en 2011

Pregabalin enhances the antinociceptive effect of oxycodone and morphine in thermal models of nociception in the rat without any pharmacokinetic interactions.

artículo científico publicado en 2015

Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial

artículo científico publicado en 2016

Rifampicin reduces plasma concentrations of celiprolol

artículo científico publicado en 2003

Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren

artículo científico publicado en 2010

Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

artículo científico

Role of OATP transporters in the disposition of drugs

scientific article published on July 2007

Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.

artículo científico publicado en 2016

SLCO1B1 polymorphism and oral antidiabetic drugs

artículo científico publicado en 2010

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

artículo científico publicado en 2006

SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren

artículo científico publicado en 2013

Safety of Single-Dose Primaquine in G6PD-Deficient and G6PD-Normal Males in Mali Without Malaria: An Open-Label, Phase 1, Dose-Adjustment Trial

artículo científico publicado en 2018

Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials

artículo científico publicado en 2018

Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen

Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide

artículo científico publicado en 2006

The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects

artículo científico publicado en 2004

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

artículo científico publicado en 2014

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

artículo científico publicado en 2012

The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.

artículo científico publicado en 2001

The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range

artículo científico publicado en 2008

The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo

artículo científico publicado en 2008

The mineralocorticoid receptor antagonist spironolactone enhances morphine antinociception

artículo científico publicado en 2013

Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin

artículo científico publicado en 2023

Transfer of repaglinide in the dually perfused human placenta and the role of organic anion transporting polypeptides (OATPs)

article

Transporter pharmacogenetics and statin toxicity

artículo científico publicado en 2009

Transporter-mediated Alterations in Patients with NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate.

artículo científico publicado en 2017

Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone

artículo científico publicado en 2007

UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo

artículo científico publicado en 2009

Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification.

artículo científico publicado en 2013

Vegan diet in young children remodels metabolism and challenges the statuses of essential nutrients

artículo científico publicado en 2021

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda